DLL3 and small cell lung carcinoma: I-DXd is under evaluation in a phase 1/2 study (NCT04471727) in combination with the DLL-3 inhibitor MK-6070 (HPN328), in a phase 3 trial (IDeate-Lung02) at the dose of 12 mg/kg versus Treatment of Physician’s Choice in relapsed SCLC, and in a phase 1/2 study (IDeate-Lung03) in combination with 1st line chemo-immunotherapy in ES-SCLC.